ENG  Vol.4 No.10 , October 2012
Anticancer Gene-engineered MSC-mediated Cancer Cell Death: An Imaging Demonstration
Abstract

This study was performed to demonstrate the transportation of an engineered MSC-produced intracellular anticancer gene product between mesenchymal stem cell (MSC) and cancer cells.  MSC-mediated anticancer strategy has held great promise owing to MSCs’ capacity of tumor-directed migration and the availability of specific anticancer genes.  All anticancer genes that have been used in previous MSC-mediated anticancer studies were limited in functioning via extracellular mechanisms, mainly because of the restriction by cell membrane to macromolecules including proteins.  In order to apply the majority of potent anticancer genes to the MSC-mediated anticancer system, a specifically designed expression vector which bears an intracellular anticancer gene, PTEN, is utilized to demonstrate the feasibility of the system in cancer therapies.  A transacting activator of transcription (TAT) was introduced into an expression vector followed by a segment for PTEN-RFP fusion protein.  A direct demonstration of PTEN-RFP transportation between MSC and cancer cells was obtained from direct co-cultures.  A marked cancer cell death was observed in indirect co-cultures with conditioned media from PTEN-transfected MSCs.  The demonstration of PTEN-engineered MSC-produced PTEN transportation indicates the feasibility of applying intracellular anticancer gene expression system in MSC-mediated strategies for cancer therapy.


Cite this paper
X. Sun, Z. Chen, M. Moniri, H. Lu, L. Dai and G. Warnock, "Anticancer Gene-engineered MSC-mediated Cancer Cell Death: An Imaging Demonstration," Engineering, Vol. 4 No. 10, 2012, pp. 35-38. doi: 10.4236/eng.2012.410B009.
References

[1]   G. Pappas, et al., "Adenoviral-mediated PTEN expression radiosensitizes non-small cell lung cancer cells by suppressing DNA repair capacity," Cancer Gene Ther, vol. 14, pp. 543-9, Jun 2007.

[2]   H. Jin, et al., "Urocanic acid-modified chitosan-mediated PTEN delivery via aerosol suppressed lung tumorigenesis in K-ras(LA1) mice," Cancer Gene Ther, vol. 15, pp. 275-83, May 2008.

[3]   C. Ren, et al., "Therapeutic potential of mesenchymal stem cells producing interferon-alpha in a mouse melanoma lung metastasis model," Stem Cells, vol. 26, pp. 2332-8, Sep 2008.

[4]   S. Kidd, et al., "Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment," Cytotherapy, vol. 12, pp. 615-25, Sep 2010.

[5]   K. Nakamura, et al., "Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model," Gene Ther, vol. 11, pp. 1155-64, Jul 2004.

[6]   S. Gunnarsson, et al., "Intratumoral IL-7 delivery by mesenchymal stromal cells potentiates IFNgamma-transduced tumor cell immunotherapy of experimental glioma," J Neuroimmunol, vol. 218, pp. 140-4, Jan 25 2010.

[7]   X. Chen, et al., "A tumor-selective biotherapy with prolonged impact on established metastases based on cytokine gene-engineered MSCs," Mol Ther, vol. 16, pp. 749-56, Apr 2008.

[8]   I. T. Cavarretta, et al., "Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth," Mol Ther, vol. 18, pp. 223-31, Jan 2010.

[9]   H. Miletic, et al., "Bystander killing of malignant glioma by bone marrow-derived tumor-infiltrating progenitor cells expressing a suicide gene," Mol Ther, vol. 15, pp. 1373-81, Jul 2007.

[10]   G. Xu, et al., "Adenoviral-mediated interleukin-18 expression in mesenchymal stem cells effectively suppresses the growth of glioma in rats," Cell Biol Int, vol. 33, pp. 466-74, Apr 2009.

[11]   M. Kanehira, et al., "Targeted delivery of NK4 to multiple lung tumors by bone marrow-derived mesenchymal stem cells," Cancer Gene Ther, vol. 14, pp. 894-903, Nov 2007.

[12]   L. G. Menon, et al., "Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy," Stem Cells, vol. 27, pp. 2320-30, Sep 2009.

[13]   M. R. Loebinger, et al., "Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer," Cancer Res, vol. 69, pp. 4134-42, May 15 2009.

[14]   X. Y. Sun, et al., "MSC(TRAIL)-mediated HepG2 cell death in direct and indirect co-cultures," Anticancer Res, vol. 31, pp. 3705-12, Nov 2011.

[15]   X. Y. Sun, et al., "Mesenchymal stem cell-mediated cancer therapy: A dual-targeted strategy of personalized medicine," World J Stem Cells, vol. 3, pp. 96-103, Nov 26 2011.

[16]   P. A. Steck, et al., "Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers," Nat Genet, vol. 15, pp. 356-62, Apr 1997.

[17]   J. Li, et al., "PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer," Science, vol. 275, pp. 1943-7, Mar 28 1997.

[18]   M. Peyrou, et al., "PTEN in liver diseases and cancer," World J Gastroenterol, vol. 16, pp. 4627-33, Oct 7 2010.

[19]   G. Pappas, et al., "Adenoviral-mediated PTEN expression radiosensitizes non-small cell lung cancer cells by suppressing DNA repair capacity," Cancer Gene Ther, vol. 14, pp. 543-9, Jun 2007.

[20]   H. Jin, et al., "Urocanic acid-modified chitosan-mediated PTEN delivery via aerosol suppressed lung tumorigenesis in K-ras(LA1) mice," Cancer Gene Ther, vol. 15, pp. 275-83, May 2008.

[21]   L. J. Dai, et al., "Potential implications of mesenchymal stem cells in cancer therapy," Cancer Lett, vol. 305, pp. 8-20, Jun 1 2011.

 
 
Top